Thrombin Generation in Newborn Plasma Is Critically Dependent on the Concentration of Prothrombin

Summary

The ability to generate thrombin is decreased and delayed in plasma from the healthy newborn infant compared to the adult. Only 30 to 50% of peak adult thrombin activity can be produced in neonatal plasma. To test whether this observation can be explained by the low neonatal levels of the contact or vitamin K dependent factors, we measured neonatal thrombin generation after raising the concentration of these factors to adult values. We also determined whether the addition of a variety of blood products to neonatal plasma improved thrombin generation. An amidolytic method was used to quantitate intrinsic (APTT) and extrinsic (PT) pathway thrombin generation in defibrinated pooled cord plasma from healthy term infants. Added individually, factors VII, IX, X or the contact factors (CF) failed to alter the rate or the total amount of thrombin generated in neonatal plasma. In contrast, the addition of prothrombin increased the total amount of thrombin generated to above adult values in both the APTT and the PT systems but did not alter the rate of thrombin generation. The rate of thrombin generation in cord plasma shortened after a combination of II, IX, X and CF was added to the APTT system or II, VII and X to the PT system. In both systems, the total amount of thrombin generated was linearly related to the initial prothrombin concentration. Each of fresh frozen plasma, cryoprecipitate, plasma from platelet concentrates, or factor IX concentrate (in amounts used therapeutically) caused an increase in the total amount of thrombin generated which was related to the increase in prothrombin concentration. Thus, the total amount of thrombin generated in newborn plasma is critically dependent on the prothrombin concentration whereas the rate at which thrombin is generated is dependent on the levels of many other coagulation proteins in combination.

Keywords

Coagulation - Prothrombin - Newborn

• References

• 1 Schmidt B, Ofosu FA, Mitchell L, Brooker LA, Andrew M. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25: 405-408
• 2 Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. The development of the human coagulation system in the full term infant. Blood 1987; 70: 165-172
• 3 Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P. Development of the coagulation system in the healthy premature infant. Blood 1988; 72: 1651-1657
• 4 Modi GJ, Blajchman MA, Ofosu FA. The isolation of prothrombin, factor IX and factor X from human factor IX concentrates. Thromb Res 1984; 36: 537-547
• 5 Nossel HL. The Contact Phase of Blood Coagulation. Blackwell Scientific Publications; Philadelphia, PA: 1964. p 45
• 6 Johnston M, Zipursky A. Microtechnology for the study of the blood coagulation system in newborn infants. Can J Med Tech 1980; 42: 159-164
• 7 Ofosu FA, Cerskus AL, Hirsh J, Smith LM, Modi GJ, Blajchmaii MA. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor. Br J Haematol 1984; 57: 229-238
• 8 Hathaway WE, Bonnar J. Perinatal coagulation. In: Monographs in Neonatology Grune and Stratton; New York: 1978. pp 53-81
• 9 Bar-Shavit R, Hruska KA, Kahn AJ, Wilner GD. Hormone-like activity of human thrombin. In: Bioregulatory Functions of Thrombin Walz DA, Fenton JW, Shuman MA. (eds) Ann NY Acad Sei; 485 335-348
• 10 Lui CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979; 254: 10421-10425
• 11 Jesty J. The kinetics of inhibition of thrombin by antithrombin in the presence of components of the hemostatic system. Blood 1985; 66: 1189-1195
• 12 Glueck HI. The utilization of a synthetic substrate (TAMc) to measure the plasma prothrombin in coagulation disorders. J Lab Clin Med 1957; 49: 41-60
• 13 Hathaway WE, Bonnar J. Perinatal coagulation. In: Monographs in Neonatology Grune and Stratton; New York: 1978. pp 115-169
• 14 Hamblelon G, Appleyard WJ. Controlled trial of fresh frozen plasma in asphyxiated low birth weight infants. Arch Dis Child 1973; 48: 31-35
• 15 Gottuso MA, Williams ML, Oski FA. The role of exchange transfusions in the management of low-birth-weight infants with and without severe respiratory distress syndrome. J Pediatr 1976; 89: 279-285
• 16 Gross SJ, Filston HC, Anderson JC. Controlled study of treatment of disseminated intravascular coagulation in the neonate. J Pediatr 1982; 100: 445-448
• 17 Zipursky A, deSa D, Hsu E, Johnston M, Milner R. Clinical and laboratory diagnosis of hemostatic disorders in newborn infants. Am J Pediatr Hematol/Oncol 1979; 1: 217-226
• 18 Blajchman MA, Sheridan D, Rawls WE. Risks associated with blood transfusion in newborn infants. Clin Perinatol 1984; 11: 403-415
• 19 Friezmer Degen SJ, MacGillivray RT A, Davie EW. Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. Biochemistry 1983; 22: 2087-2097